November 13, 2007in Cross Border Issues, Patents, Pharmaceutical Drugs1by Editor196 Good vs. Evil? India rejects Novartis claim on drug improvements India’s rejection of Novartis’ claim on drug improvements highlights the flexibility of India’s patent laws. Such flexibility stands in sharp contrast to the World Trade Organization’s efforts to set standards…
